Functional response to cardiac resynchronization therapy is associated with improved clinical outcome and absence of

Nick Van Boven1, Kjell Bogaard, Jaap Ruiter

  • 1Department of Cardiology, Medical Centre Alkmaar (MCA), Alkmaar, The Netherlands.

Insights

Patients receiving CRT-D for chronic heart failure (CHF) who respond functionally have excellent outcomes and rarely require defibrillator therapy. Left bundle branch block and longer QRS duration predict positive functional response.

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • Chronic heart failure (CHF) patients treated with CRT-D require evaluation of clinical outcomes and shock incidence.
  • Functional response status is a key factor in predicting outcomes for these patients.

Purpose of the Study:

  • To evaluate clinical outcomes and shock incidence in CHF patients treated with CRT-D based on functional response.
  • To identify predictors of functional response to CRT-D therapy.

Main Methods:

  • 179 consecutive CHF patients receiving CRT-D between 2005-2010 were analyzed.
  • Functional responders were defined as those with left ventricular ejection fraction (LVEF) ≥ 35% postimplantation.
  • Endpoints included all-cause mortality, heart failure hospitalizations, and appropriate/inappropriate shocks.

Main Results:

  • Functional responders (n=42) experienced no deaths, HF hospitalizations, or appropriate shocks; 7.1% received inappropriate shocks.
  • Non-responders (n=100) had 22% mortality, 17% HF hospitalizations, and 17% appropriate shocks (P < 0.007 for all).
  • Left bundle branch block (LBBB), QRS duration ≥ 150 ms, and no baseline diuretic use predicted functional response.

Conclusions:

  • Functional responders to CRT-D demonstrate a favorable prognosis with minimal need for ICD therapy.
  • LBBB, prolonged QRS duration, and absence of chronic diuretic use are independent predictors of CRT-D functional response.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...